These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24874896)

  • 1. Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one.
    Gabano E; Ravera M; Osella D
    Dalton Trans; 2014 Jul; 43(26):9813-20. PubMed ID: 24874896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D
    J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D
    Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
    Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fresh platinum complexes with promising antitumor activity.
    Wang X
    Anticancer Agents Med Chem; 2010 Jun; 10(5):396-411. PubMed ID: 20545618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photoactivatable platinum complexes.
    Bednarski PJ; Mackay FS; Sadler PJ
    Anticancer Agents Med Chem; 2007 Jan; 7(1):75-93. PubMed ID: 17266506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E; Gibson D
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
    Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
    ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Gibson D
    J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.
    Fronik P; Poetsch I; Kastner A; Mendrina T; Hager S; Hohenwallner K; Schueffl H; Herndler-Brandstetter D; Koellensperger G; Rampler E; Kopecka J; Riganti C; Berger W; Keppler BK; Heffeter P; Kowol CR
    J Med Chem; 2021 Aug; 64(16):12132-12151. PubMed ID: 34403254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
    Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
    J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV) Prodrugs.
    Venkatesh V; Sadler PJ
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
    ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safe and efficacious Pt(ii) anticancer prodrug: design, synthesis, in vitro efficacy, the role of carrier ligands and in vivo tumour growth inhibition.
    Dutta PK; Sharma R; Kumari S; Dubey RD; Sarkar S; Paulraj J; Vijaykumar G; Pandey M; Sravanti L; Samarla M; Das HS; Yashpal ; B H; Goyal R; Gupta N; Mandal SK; Sengupta A; Sarkar A
    Chem Commun (Camb); 2019 Feb; 55(12):1718-1721. PubMed ID: 30623966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur-donor biomolecules.
    Bugarčić ŽD; Bogojeski J; Petrović B; Hochreuther S; van Eldik R
    Dalton Trans; 2012 Oct; 41(40):12329-45. PubMed ID: 22890549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds.
    Zuccolo M; Arrighetti N; Perego P; Colombo D
    Curr Med Chem; 2022; 29(15):2566-2601. PubMed ID: 34365939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.
    Jayawardhana AMDS; Zheng YR
    Dalton Trans; 2022 Feb; 51(5):2012-2018. PubMed ID: 35029256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.